Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)Symptoms, Doctors, Treatments, Advances & More
Learn About Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Bruce Tan is an Otolaryngologist in Chicago, Illinois. Dr. Tan has been practicing medicine for over 22 years and is rated as an Elite provider by MediFind in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). His top areas of expertise are Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Nasal Polyps, Sinusitis, Endoscopy, and Nerve Decompression.
Robert Kern is an Otolaryngologist in Chicago, Illinois. Dr. Kern has been practicing medicine for over 41 years and is rated as an Elite provider by MediFind in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). His top areas of expertise are Nasal Polyps, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Asthma, Endoscopy, and Nerve Decompression.
David Conley is an Otolaryngologist in Chicago, Illinois. Dr. Conley has been practicing medicine for over 37 years and is rated as an Elite provider by MediFind in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). His top areas of expertise are Nasal Polyps, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Asthma, Endoscopy, and Nerve Decompression.
Summary: This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 56 weeks per participant, 52 weeks of treatment period, and 4 weeks ...
Summary: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.